Protein arrays are lagging behind in their implementation relative to DNA arrays because proteins are harder to produce and keep active. But in the September Nature Biotechnology de Wildt et al.

Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have ...

The AntibodyArray is a membrane on which antibodies to a variety of protein ligands are immobilized. Users of the technology apply a cell lysate to the array and incubate to allow proteins to bind to ...

Monoclonal antibodies (mAbs) are one of the most successful therapeutic drug classes, generating lucrative sales for the pharmaceutical industry. In 2016, more than 20 therapeutic antibodies gained ...

A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) ...